Journal
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA
Volume 30, Issue 3, Pages 323-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.iac.2010.06.004
Keywords
Atopic dermatitis; Atopic keratoconjunctivitis; Ocular allergy; Blepharoconjunctivitis; Keratoconus
Categories
Funding
- Schering-Plough
- Glaxo-Smith-Kline
- Merck
- Otsuka
- Novartis
- Sanofi-Aventis
- Genentech
- UCB-Pharma
- Alcon
- Meda
- Inspire
- Santen
- Allergan
- ISTA
- SARCode
- Bausch and Lomb
- Vistakon
- ViroPharm
- Dyax
- Jerini
- Ocusense (Tear Lab)
- Rutgers University Press
- Astellas
Ask authors/readers for more resources
Atopic dermatitis, a chronic disease seen by allergist-immunologists, has both dermatologic and ocular manifestations. The ocular component is often disproportionately higher than the dermatologic disease. Even if skin abnormalities seem well controlled, these patients require ophthalmic evaluation. Atopic keratoconjunctivitis in atopic dermatitis patients is characterized by acute exacerbations and requires maintenance therapy for long-term control. Future studies will continue to emphasize the use of steroid-sparing, immunomodulating agents that have the potential to provide long-lasting anti-inflammatory control with a more favorable side-effect profile.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available